

Advances in a dynamic disease: A patient-first approach to HR-positive mBC

Wednesday 15th May, 18:30 – 19:30 (CEST)
Frankfurt Hall, Hub27, Berlin

Join us for an interactive case-based discussion to explore:

- New strategies to optimise ET-based combinations by targeting the underlying disease biology in the post-CDK4/6i setting
- Latest advances in the post-ET treatment landscape, reviewing key emerging ADCs
- Best practices to optimise patient management and outcomes

Faculty:



Chair Speaker
Professor Sibylle Loibl
Goethe University of Frankfurt, Germany



Dr Mafalda Oliveira
Vall d'Hebron University Hospital,
Barcelona, Spain



Dr Aditya Bardia
University of California, Los Angeles, USA

Time CEST	Advances in a dynamic disease: A patient-first approach to HR-positive mBC	Speaker
18:30–18:35	The evolving treatment paradigm in HR-positive, HER2-negative/low mBC	Sibylle Loibl
18:35–18:45	Targeted strategies: ET-based combinations in 2L HR-positive disease	Mafalda Oliveira
18:45–18:55	New frontiers: Exploring options post-ET with ADCs	Aditya Bardia
18:55–19:25	Putting patients first: An interactive case discussion	Chair: Sibylle Loibl Panel: Mafalda Oliveira, Aditya Bardia
19:25–19:30	Summary and close	Sibylle Loibl